Please use this identifier to cite or link to this item: https://hdl.handle.net/1959.11/31277
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBurke, Amy Cen
dc.contributor.authorTelford, Dawn Een
dc.contributor.authorSutherland, Brian Gen
dc.contributor.authorEdwards, Jane Yen
dc.contributor.authorSawyez, Cynthia Gen
dc.contributor.authorBarrett, P Hugh Ren
dc.contributor.authorNewton, Roger Sen
dc.contributor.authorPickering, J Geoffreyen
dc.contributor.authorHuff, Murray Wen
dc.date.accessioned2021-08-11T04:11:48Z-
dc.date.available2021-08-11T04:11:48Z-
dc.date.issued2018-05-
dc.identifier.citationArteriosclerosis, Thrombosis, and Vascular Biology, 38(5), p. 1178-1190en
dc.identifier.issn1524-4636en
dc.identifier.issn1079-5642en
dc.identifier.urihttps://hdl.handle.net/1959.11/31277-
dc.description.abstract<p><i><b>Objective</b></i>—Bempedoic acid (BemA; ETC-1002) is a novel drug that targets hepatic ATP-citrate lyase to reduce cholesterol biosynthesis. In phase 2 studies, BemA lowers elevated low-density lipoprotein cholesterol (LDL-C) in hypercholesterolemic patients. In the present study, we tested the ability of BemA to decrease plasma cholesterol and LDL-C and attenuate atherosclerosis in a large animal model of familial hypercholesterolemia.</p><p> <i><b>Approach and Results</b></i>—Gene targeting has been used to generate Yucatan miniature pigs heterozygous (<i>LDLR<sup>+/−</sup></i>) or homozygous (<i>LDLR<sup>−/−</sup></i>) for LDL receptor deficiency (ExeGen). <i>LDLR<sup>+/−</sup></i> and <i>LDLR<sup>−/−</i></sup></sup></i> pigs were fed a high-fat, cholesterol-containing diet (34% kcal fat; 0.2% cholesterol) and orally administered placebo or BemA for 160 days. In <i>LDLR<sup>+/−</sup></i> pigs, compared with placebo, BemA decreased plasma cholesterol and LDL-C up to 40% and 61%, respectively. In <i>LDLR<sup>−/−</sup></i> pigs, in which plasma cholesterol and LDL-C were 5-fold higher than in <i>LDLR<sup>+/−</sup></i> pigs, BemA decreased plasma cholesterol and LDL-C up to 27% and 29%, respectively. Plasma levels of triglycerides and high-density lipoprotein cholesterol, fasting glucose and insulin, and liver lipids were unaffected by treatment in either genotype. In the aorta of <i>LDLR<sup>+/−</sup></i> pigs, BemA robustly attenuated en face raised lesion area (−58%) and left anterior descending coronary artery cross-sectional lesion area (−40%). In <i>LDLR<sup>−/−</sup></i> pigs, in which lesions were substantially more advanced, BemA decreased aortic lesion area (−47%) and left anterior descending coronary artery lesion area (−48%).</p><p> <i><b>Conclusions</b></i>—In a large animal model of <i>LDLR</i> deficiency and atherosclerosis, long-term treatment with BemA reduces LDL-C and attenuates the development of aortic and coronary atherosclerosis in both <i>LDLR<sup>+/−</sup></i> and <i>LDLR<sup>−/−</sup></i> miniature pigs.</p>en
dc.languageenen
dc.publisherLippincott Williams & Wilkinsen
dc.relation.ispartofArteriosclerosis, Thrombosis, and Vascular Biologyen
dc.titleBempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient (LDLR+/− and LDLR−/−) Yucatan Miniature Pigsen
dc.typeJournal Articleen
dc.identifier.doi10.1161/ATVBAHA.117.310676en
dc.identifier.pmid29449335en
dcterms.accessRightsGolden
local.contributor.firstnameAmy Cen
local.contributor.firstnameDawn Een
local.contributor.firstnameBrian Gen
local.contributor.firstnameJane Yen
local.contributor.firstnameCynthia Gen
local.contributor.firstnameP Hugh Ren
local.contributor.firstnameRoger Sen
local.contributor.firstnameJ Geoffreyen
local.contributor.firstnameMurray Wen
local.profile.schoolFaculty of Medicine and Healthen
local.profile.emailpbarret6@une.edu.auen
local.output.categoryC1en
local.record.placeauen
local.record.institutionUniversity of New Englanden
local.publisher.placeUnited States of Americaen
local.format.startpage1178en
local.format.endpage1190en
local.identifier.scopusid85053133306en
local.peerreviewedYesen
local.identifier.volume38en
local.identifier.issue5en
local.access.fulltextYesen
local.contributor.lastnameBurkeen
local.contributor.lastnameTelforden
local.contributor.lastnameSutherlanden
local.contributor.lastnameEdwardsen
local.contributor.lastnameSawyezen
local.contributor.lastnameBarretten
local.contributor.lastnameNewtonen
local.contributor.lastnamePickeringen
local.contributor.lastnameHuffen
dc.identifier.staffune-id:pbarret6en
local.profile.orcid0000-0003-3223-6125en
local.profile.roleauthoren
local.profile.roleauthoren
local.profile.roleauthoren
local.profile.roleauthoren
local.profile.roleauthoren
local.profile.roleauthoren
local.profile.roleauthoren
local.profile.roleauthoren
local.profile.roleauthoren
local.identifier.unepublicationidune:1959.11/31277en
local.date.onlineversion2018-02-15-
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
local.title.maintitleBempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient (LDLR+/− and LDLR−/−) Yucatan Miniature Pigsen
local.relation.fundingsourcenoteThis work was supported by grants to M.W. Huff from Esperion Therapeutics Inc, Ann Arbor, MI, and the Canadian Institutes for Health Research (MOP-126045). A.C. Burke was supported by a Doctoral Award from the Canadian Diabetes Association (DS-3-14-4588-AB).en
local.output.categorydescriptionC1 Refereed Article in a Scholarly Journalen
local.search.authorBurke, Amy Cen
local.search.authorTelford, Dawn Een
local.search.authorSutherland, Brian Gen
local.search.authorEdwards, Jane Yen
local.search.authorSawyez, Cynthia Gen
local.search.authorBarrett, P Hugh Ren
local.search.authorNewton, Roger Sen
local.search.authorPickering, J Geoffreyen
local.search.authorHuff, Murray Wen
local.uneassociationNoen
local.atsiresearchNoen
local.sensitive.culturalNoen
local.year.available2018en
local.year.published2018en
local.fileurl.closedpublishedhttps://rune.une.edu.au/web/retrieve/d7f29c2a-285e-4e02-8457-9f9cb53d7f13en
local.subject.for2020320101 Cardiology (incl. cardiovascular diseases)en
local.subject.for2020320803 Systems physiologyen
local.subject.seo2020200105 Treatment of human diseases and conditionsen
dc.notification.token2146cd68-dc7a-4fc6-a468-860e7471c014en
Appears in Collections:Journal Article
Files in This Item:
1 files
File SizeFormat 
Show simple item record

SCOPUSTM   
Citations

36
checked on Jun 29, 2024

Page view(s)

850
checked on Jul 23, 2023

Download(s)

4
checked on Jul 23, 2023
Google Media

Google ScholarTM

Check

Altmetric


Items in Research UNE are protected by copyright, with all rights reserved, unless otherwise indicated.